Low antibiotic doses combat Golden Staph

February 20, 2015 by Narelle Towie, Science Network WA
Dr Boulos and his team tested the drug on worms and cured them of infection. Credit: National Eye Institute

Local chemists have helped develop a class of antibiotics that kills drug-resistant superbugs in low doses.

Australian and US researchers used 3D computer modelling to design the new antibiotic, called Compound 10, and found that it can kill drug-resistant Staphylococcus aureus in worms at doses 10 times lower than other commonly used .

Methicillin-resistant Staphylococcus aureus (MRSA), also known as Golden Staph, is a growing problem in WA hospitals, leaving first-line antibiotics powerless to stop infection and significantly increasing rates of illness and death.

The new drug targets a bacteria-specific protein, called the mechanosensitive ion channel of large conductance (MscL), which stops the bacteria's from rupturing by acting as a valve and releasing solutes.

Flinders University research associate Dr Ramiz Boulos says MscL was an ideal target for drug research because it sits on the outer membrane of nearly all bacteria, but is not found in the human genome.

"What we have designed here is antibiotics that allow the bacteria to vomit to a point where they become really weak and they either die or they can be overcome by the host," Dr Boulos says.

Low antibiotic doses combat Golden Staph
A ball and stick representation of the antibiotic. Credit: Ramiz Boulos

"What the antibiotics do is they open this channel (MscL) more frequently and for longer periods of time."

UWA biochemist Edwin Tjandra, who spent months testing the toxicity of the drug on cultured , says the discovery is a major breakthrough in the battle against superbugs.

"I was looking at what concentration the drug kills immortalised skin cells and found there was no toxicity to eukaryotic cells until we used doses 10 times the minimum inhibitory concentration," Mr Tjandra says.

"I think it's very important for the treatment of MRSA."

Dr Boulos and his team tested the on worms and cured them of infection.

They hope that within five years, Compound 10 will move into human clinical trials, following more animal studies.

Dr Boulos says some of the compounds he was working with are new to chemistry and his team were extremely excited to find Compound 10 not only has antibacterial properties but is also so highly effective at killing Staphylococcus.

In low doses, Compound 10 did not harm the worm's cells (or had low cytotoxicity) but was highly potent to the bacteria.

"In the worm infection model we started to see therapeutic effects from 0.2 micrograms per milliltre."

"The cytotoxicity concentration occurs at 50 micrograms per milliltre, so that's a 250 fold difference, and that's much better than commercial antibiotics.

Explore further: New antibiotic holds promise against antibiotic-resistant infections

Related Stories

New antibiotic holds promise against antibiotic-resistant infections

February 16, 2015
Estimates of deaths from methicillin-resistant Staphylococcus aureus (MRSA) in the United States range upwards of 19,000 annually. Around 1960, when Staphylococcus aureus developed resistance to first-generation penicillin, ...

Getting ahead of antibiotic-resistant bacteria

February 6, 2015
The prevalence of antibiotic-resistant bacteria has turned new drug development into a high-stakes chess game, with researchers always trying to anticipate a disease bacteria's next move or mutation to make sure new antibiotics ...

Scientists develop compound to fight MRSA

January 29, 2015
Microbiologists and chemists at the University of South Florida have developed and patented a synthetic compound that has shown antibiotic action against methicillin resistant Staphylococcus aureus, also known as MRSA, which ...

Recommended for you

New strategy to cure chronic hepatitis B infection

May 18, 2018
Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption. ...

Blood type affects severity of diarrhea caused by E. coli

May 17, 2018
A new study shows that a kind of E. coli most associated with "travelers' diarrhea" and children in underdeveloped areas of the world causes more severe disease in people with blood type A.

Resistance to antifungal drugs could lead to disease and global food shortages

May 17, 2018
Growing levels of resistance to antifungal treatments could lead to increased disease outbreaks and affect food security around the world.

Pig immunology comes of age: Killer T cell responses to influenza

May 17, 2018
Researchers from The Pirbright Institute, University of Bristol, Cardiff University and University of Oxford have generated tools that allow scientists to understand a vital area of the pig immune system which was previously ...

How intestinal worms hinder tuberculosis vaccination

May 17, 2018
New research in mice suggests that chronic infection with intestinal worms indirectly reduces the number of cells in lymph nodes near the skin, inhibiting the immune system's response to the Bacille Calmette-Guerin (BCG) ...

Mosquito spit may affect your immune system for days

May 17, 2018
Mosquito saliva alone—even in the absence of any pathogens—contains hundreds of proteins. Now, researchers reporting in PLOS Neglected Tropical Diseases have discovered that the interaction of these proteins with the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.